120 related articles for article (PubMed ID: 2985238)
1. Defective interleukin-1 production by natural killer cells of patients with cancer.
Herman J; Kew MC; Rabson AR
Cancer Immunol Immunother; 1985; 19(2):148-53. PubMed ID: 2985238
[TBL] [Abstract][Full Text] [Related]
2. The effect of RU 41.740 (Biostim) on the production of interleukin-1 by monocytes and enriched large granular lymphocytes in normals and patients with hepatocellular carcinoma.
Herman J; Kew MC; Rabson AR
Cancer Immunol Immunother; 1986; 21(1):26-30. PubMed ID: 3002605
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells stimulate interleukin 1 (IL-1) production from enriched large granular lymphocytes.
Herman J; Rabson AR
Clin Immunol Immunopathol; 1986 Mar; 38(3):282-94. PubMed ID: 2417768
[TBL] [Abstract][Full Text] [Related]
4. The role of interleukin 1 (IL 1) in tumor-NK cell interactions: correction of defective NK cell activity in cancer patients by treating target cells with IL 1.
Herman J; Dinarello CA; Kew MC; Rabson AR
J Immunol; 1985 Oct; 135(4):2882-6. PubMed ID: 2993420
[TBL] [Abstract][Full Text] [Related]
5. Depressed natural cytotoxicity but normal natural killer cytotoxic factor (NKCF) production by mononuclear cells derived from patients with hepatocellular carcinoma.
Brookes RH; Kew MC; Rabson AR
Cancer Immunol Immunother; 1987; 25(2):149-52. PubMed ID: 2822243
[TBL] [Abstract][Full Text] [Related]
6. Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole.
Son K; Kew M; Rabson AR
Cancer; 1982 Dec; 50(12):2820-5. PubMed ID: 6182983
[TBL] [Abstract][Full Text] [Related]
7. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
[TBL] [Abstract][Full Text] [Related]
8. Distinct granzyme expression in human CD3- CD56+ large granular- and CD3- CD56+ small high density-lymphocytes displaying non-MHC-restricted cytolytic activity.
Smyth MJ; Browne KA; Kinnear BF; Trapani JA; Warren HS
J Leukoc Biol; 1995 Jan; 57(1):88-93. PubMed ID: 7530284
[TBL] [Abstract][Full Text] [Related]
9. Defective interleukin-1 production by monocytes from patients with malignant disease. Interferon increases IL-1 production.
Herman J; Kew MC; Rabson AR
Cancer Immunol Immunother; 1984; 16(3):182-5. PubMed ID: 6608404
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
11. Assessment of lymphokine-activated killer activity and gamma-interferon production in patients with small hepatocellular carcinomas.
Saibara T; Maeda T; Miyazaki M; Onishi S; Yamamoto Y
Hepatology; 1993 May; 17(5):781-7. PubMed ID: 7684018
[TBL] [Abstract][Full Text] [Related]
12. Production of interleukin 1 but not of procoagulant activity by large granular lymphocytes.
Rambaldi A; Alessio G; Rossi V; Donati MB; Semeraro N; Mantovani A
Scand J Immunol; 1985 Oct; 22(4):363-6. PubMed ID: 3877977
[TBL] [Abstract][Full Text] [Related]
13. Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon alpha or gamma, human recombinant interleukin-2 and indomethacin.
Conti P; Reale M; Angeletti PU; Dinarello CA
Int J Immunopharmacol; 1988; 10(8):907-11. PubMed ID: 3145923
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.
Sibbitt WL; Mathews PM; Bankhurst AD
J Clin Invest; 1983 May; 71(5):1230-9. PubMed ID: 6853711
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 depresses natural cytotoxicity by inhibiting interleukin-1 production by large granular lymphocytes.
Herman J; Rabson AR
Clin Exp Immunol; 1984 Aug; 57(2):380-4. PubMed ID: 6331926
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
Hogan PG; Hapel AJ; Doe WF
J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
[TBL] [Abstract][Full Text] [Related]
17. Defective NK cell activity following thermal injury.
Klimpel GR; Herndon DN; Fons M; Albrecht T; Asuncion MT; Chin R; Stein MD
Clin Exp Immunol; 1986 Nov; 66(2):384-92. PubMed ID: 3493101
[TBL] [Abstract][Full Text] [Related]
18. Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.
Shirai M; Watanabe S; Nishioka M
Hepatogastroenterology; 1990 Oct; 37(5):465-8. PubMed ID: 2174825
[TBL] [Abstract][Full Text] [Related]
19. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
Ujiie T
Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2.
Bonavida B; Katz J; Gottlieb M
J Immunol; 1986 Aug; 137(4):1157-63. PubMed ID: 3488345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
